



February 15, 2024



Central Japan Railway Company
West Japan Railway Company
A s t r a Z e n e c a K . K .

Launch of a Service to Achieve Net Zero CO₂ Emissions on the Tokaido and Sanyo Shinkansen

Central Japan Railway Company (President and Representative Director: Shunsuke Niwa; hereinafter referred to as “JR Central”) and West Japan Railway Company (President and Representative Director: Kazuaki Hasegawa; hereinafter referred to as “JR West”) are committed to creating a sustainable society through global environmental conservation. With the aim of realizing this, the two companies have considered providing the corporate members of the EX Reservation Service with a service that uses CO₂-free electricity to achieve net zero CO₂ emissions associated with traveling on the Shinkansen, which will be the first of its kind in Japan, and have worked with AstraZeneca K.K. (President and Representative Director: Takafumi Horii; hereinafter referred to as “AstraZeneca”) as a partner. We would like to inform you that we have decided to start the service.

By rolling out this service, we will create an environment where customers who are interested in preserving the global environment can use the Tokaido and Sanyo Shinkansen with greater peace of mind.

1. Service Overview (See [Attachment 1](#) for details.)

- (1) Scheme: ① JR Central and JR West purchase CO₂-free electricity* from power companies.
② CO₂-free electricity is allocated to business trips by the corporate members of the EX Reservation Service.
(The corporate members of the EX Reservation Service pay additional charges for purchasing CO₂-free electricity.)
③ JR Central and JR West issue a certificate that validates CO₂ reduction effects to the corporate members of the EX Reservation Service.
* CO₂-free electricity: Electricity with a non-fossil certificate that is derived from renewable energy sources, such as solar power generation, that do not emit CO₂ during power generation

(2) Start Date: April 2024

(3) Benefits : Net zero CO₂ emissions (Scope 3*) associated with the use of the Tokaido and Sanyo Shinkansen by the corporate members of the Express Reservation Service

* Scope 3: CO₂ emissions of other companies related to business activities

2. Background to This Collaboration

JR Central and JR West have worked to reduce CO₂ emissions associated with railway travel and to promote understanding of the environmental superiority of railways through efforts such as publishing CO₂ emissions between each station on the Tokaido and Sanyo Shinkansen.

AstraZeneca, a corporate member of the EX Express Service, is a global science-led biopharmaceutical company. With the belief that the health of society and the planet is essential to achieving people’s health, it has positioned evidence-based environmental measures as a strategic priority. Domestically, since 2019, it has worked on CO₂ emission countermeasures for the travel of employees and has adopted the concept of a CO₂ budget* for business trips. In this process, each company came to a consensus regarding their initiatives, and it was decided that the three companies would work together to create a scheme for this service.

* CO₂ budget: Concept of setting an upper limit on CO₂ emissions associated with business trips

* See [Attachment 2](#) for details of AstraZeneca’s environmental conservation efforts.



3. Contact regarding This Service

JR Central EX Reservation Sales Promotion Group tokyo-sales@jr-central.co.jp

Launch of a Service to Achieve Net Zero CO₂ Emissions on the Tokaido and Sanyo Shinkansen

<Service Scheme (image)>

③ Provision of travel services with net zero CO₂ emissions on the Tokaido and Sanyo Shinkansen



④ Use of travel services with net zero CO₂ emissions for business trips on the Tokaido and Sanyo Shinkansen (Payment of additional fees)

① Purchase of CO₂-free electricity

AstraZeneca K.K.

AstraZeneca is a global, science-led biopharmaceutical company. In Japan, it works to further contribute to the health of patients and the development of medical care, mainly focusing on cancer, cardiovascular/renal/metabolic diseases, respiratory/immune diseases, and vaccines/immunotherapy.

Company Profile

- Head Office: Osaka City, Osaka Prefecture
- Inauguration: January 2000
- Sales in 2022: \$4,110 million¹
- Number of employees: Approximately 3,600 people



Comment from Takafumi Horii President and Representative Director, AstraZeneca K.K.

“Climate change is said to be one of the largest public health crises of the 21st century. Climate change-related deaths are expected to exceed those caused by COVID-19.² To confront this crisis, society as a whole must work together to make significant changes.

We believe that it is essential to work on reducing CO₂ emissions, and that companies need to take a more proactive approach. We hope that this scheme will contribute to the promotion of Scope3 reduction and the establishment of a new standard for corporate environmental conservation.”

AstraZeneca’s Commitment to Decarbonization

With the belief that “the health of society and the planet is essential to achieving people’s health,” AstraZeneca promotes initiatives based on scientific evidence on a global scale, aiming to be carbon negative by 2030 and achieve net zero CO₂ emissions by 2045.

Initiatives as a Pioneer in Decarbonization in Japan

Scope 1 (direct CO₂ emissions from the company): The largest-scale introduction of battery electric vehicles (BEVs) in Japan (approximately 60%)

Scope 2 (indirect CO₂ emissions associated with the use of supplied electricity, etc.):

- Completed conversion to substantial renewable energy at all domestic sites (by the end of 2022)

Scope 3 (CO₂ emissions of other companies related to business activities):

- In 2019, “Smart Travel” was introduced to switch from airplanes to the Shinkansen for business trips between Tokyo and Osaka.
- The introduction of the new scheme jointly with Central Japan Railway Company and West Japan Railway Company will reduce CO₂ emissions by an estimated 184 tons between Tokyo and Hakata on the Tokaido and Sanyo Shinkansen.

1. Including revenue from Alexion Pharmaceutical’s Rare Disease Department

2. In the case of calculating and comparing the number of deaths by year based on the United Nations’ climate change-related deaths (<https://www.un.org/sites/un2.un.org/files/2021/08/fastfacts-health.pdf>) and the cumulative death toll data from the WHO Coronavirus (COVID-19) Dashboard (<https://covid19.who.int/>)